Q Chip and ARTES Biotechnology announce collaboration to develop sustained release formulations of therapeutic proteins

04-May-2010 - United Kingdom

Q Chip Ltd and ARTES Biotechnology GmbH announced that they have signed a Collaborative Agreement to explore the development of a new sustained release formulations of interferon alpha 2a for the treatment of chronic hepatitis B and C.

The collaboration aims to improve patient compliance and provide a more convenient dosing schedule compared with the current marketed pegylated therapies which require weekly administration. Q Chip will be developing a one month sustained release microsphere formulation This first phase of the collaboration is expected to be completed by the end of 2010.

The study is designed to evaluate Q Chip’s Q-Sphera™ peptide and protein delivery platform to develop a new sustained release microsphere composed of biocompatible polymers. The microsphere will be loaded with interferon alpha 2a manufactured from ARTES´ proprietary yeast Hansenula polymorpha expression system. ARTES will supply interferon alpha 2a and Q Chip will formulate the Q-Sphera microspheres.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance